Peripheral Arterial Disease in Patients with Atrial Fibrillation : The AFFIRM Study
Copyright © 2020 Elsevier Inc. All rights reserved..
BACKGROUND: Peripheral arterial disease has been linked with worse outcomes in patients with atrial fibrillation. The aim of this study is to assess the impact of peripheral arterial disease on mortality and stroke in a cohort of patients with atrial fibrillation.
METHODS: This was an ancillary analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial. A comparison of baseline characteristics was made between patients with atrial fibrillation with and without diagnosed peripheral arterial disease. Multivariate cox regression analysis was performed to compare the risk of stroke, death, and cardiovascular death among the two groups.
RESULTS: The prevalence of peripheral arterial disease in the whole cohort of 4060 patients with atrial fibrillation was 6.7%. Patients with peripheral arterial disease tended to be older; had higher prevalence of diabetes mellitus, hypertension, and smoking; and were more likely to have a history of coronary artery disease, heart failure, cardiac surgery or cardiac intervention, and stroke or transient ischemic attack (all P < .05). After multivariate adjustment, peripheral arterial disease was significantly associated with overall higher mortality (hazard ratio 1.34, 95% confidence interval 1.06-1.70, P = .016) in patients with atrial fibrillation, but the rates of ischemic stroke were similar in the two groups (3.9% vs 3.5%, P = 0.874). Subgroup analysis confined to the patients with non-anticoagulated atrial fibrillation showed that peripheral arterial disease was an independent predictor of ischemic stroke (hazard ratio 3.37, 95% confidence interval 1.25-9.09, P < .016).
CONCLUSION: Peripheral arterial disease predicts higher mortality in atrial fibrillation, and was an independent predictor of ischemic stroke in patients with non-anticoagulated atrial fibrillation. Proactive surveillance and optimization of medical management in this group of patients is warranted, given the high risks associated with peripheral arterial disease where atrial fibrillation is also present.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
|---|---|
| Enthalten in: |
The American journal of medicine - 134(2021), 4 vom: 06. Apr., Seite 514-518 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vitalis, Antonios [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atrial fibrillation |
|---|
| Anmerkungen: |
Date Completed 07.05.2021 Date Revised 24.02.2022 published: Print-Electronic CommentIn: Am J Med. 2021 May;134(5):e353. - PMID 33276947 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjmed.2020.08.026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315278986 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315278986 | ||
| 003 | DE-627 | ||
| 005 | 20231225154550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjmed.2020.08.026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315278986 | ||
| 035 | |a (NLM)32956630 | ||
| 035 | |a (PII)S0002-9343(20)30799-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vitalis, Antonios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Peripheral Arterial Disease in Patients with Atrial Fibrillation |b The AFFIRM Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.05.2021 | ||
| 500 | |a Date Revised 24.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Med. 2021 May;134(5):e353. - PMID 33276947 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Peripheral arterial disease has been linked with worse outcomes in patients with atrial fibrillation. The aim of this study is to assess the impact of peripheral arterial disease on mortality and stroke in a cohort of patients with atrial fibrillation | ||
| 520 | |a METHODS: This was an ancillary analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial. A comparison of baseline characteristics was made between patients with atrial fibrillation with and without diagnosed peripheral arterial disease. Multivariate cox regression analysis was performed to compare the risk of stroke, death, and cardiovascular death among the two groups | ||
| 520 | |a RESULTS: The prevalence of peripheral arterial disease in the whole cohort of 4060 patients with atrial fibrillation was 6.7%. Patients with peripheral arterial disease tended to be older; had higher prevalence of diabetes mellitus, hypertension, and smoking; and were more likely to have a history of coronary artery disease, heart failure, cardiac surgery or cardiac intervention, and stroke or transient ischemic attack (all P < .05). After multivariate adjustment, peripheral arterial disease was significantly associated with overall higher mortality (hazard ratio 1.34, 95% confidence interval 1.06-1.70, P = .016) in patients with atrial fibrillation, but the rates of ischemic stroke were similar in the two groups (3.9% vs 3.5%, P = 0.874). Subgroup analysis confined to the patients with non-anticoagulated atrial fibrillation showed that peripheral arterial disease was an independent predictor of ischemic stroke (hazard ratio 3.37, 95% confidence interval 1.25-9.09, P < .016) | ||
| 520 | |a CONCLUSION: Peripheral arterial disease predicts higher mortality in atrial fibrillation, and was an independent predictor of ischemic stroke in patients with non-anticoagulated atrial fibrillation. Proactive surveillance and optimization of medical management in this group of patients is warranted, given the high risks associated with peripheral arterial disease where atrial fibrillation is also present | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Peripheral arterial disease | |
| 700 | 1 | |a Shantsila, Alena |e verfasserin |4 aut | |
| 700 | 1 | |a Proietti, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Vohra, Rajiv K |e verfasserin |4 aut | |
| 700 | 1 | |a Kay, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Olshansky, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of medicine |d 1946 |g 134(2021), 4 vom: 06. Apr., Seite 514-518 |w (DE-627)NLM000114472 |x 1555-7162 |7 nnns |
| 773 | 1 | 8 | |g volume:134 |g year:2021 |g number:4 |g day:06 |g month:04 |g pages:514-518 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjmed.2020.08.026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 134 |j 2021 |e 4 |b 06 |c 04 |h 514-518 | ||